S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
All the trading advice you’ve ever received boils down to this (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
All the trading advice you’ve ever received boils down to this (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
All the trading advice you’ve ever received boils down to this (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
All the trading advice you’ve ever received boils down to this (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Cytek Biosciences Stock Price, News & Analysis (NASDAQ:CTKB)

$7.42
+0.06 (+0.82%)
(As of 12/5/2023 ET)
Compare
Today's Range
$7.22
$7.48
50-Day Range
$4.10
$7.42
52-Week Range
$3.80
$13.77
Volume
1.08 million shs
Average Volume
1.01 million shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
39.3% Upside
$10.33 Price Target
Short Interest
Bearish
7.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$730,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.12) to ($0.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

706th out of 948 stocks

Analytical Instruments Industry

18th out of 27 stocks


CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Massive Insider Trade At Cytek Biosciences
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
688
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.33
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+39.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$2.58 million
Pretax Margin
-8.58%

Debt

Sales & Book Value

Annual Sales
$183.12 million
Cash Flow
$0.08 per share
Book Value
$3.16 per share

Miscellaneous

Free Float
113,997,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.32
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 59)
    President, CEO & Chairman of the Board
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 60)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 48)
    General Counsel & Corporate Secretary
    Comp: $535.98k
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Chief Financial Officer
    Comp: $412.54k
  • Mr. Chris Williams (Age 54)
    Chief Operating Officer
  • Mr. Paul D. Goodson
    Head of Investor Relations
  • Dr. Allen B. Poirson Ph.D. (Age 63)
    Senior Vice President of Business & Corporate Development
  • Dr. Philippe Busque Ph.D.
    Senior Vice President of Global Sales & Services
  • Ms. Connie Wedel
    Chief People Officer
  • Mr. Melik Ulusu
    Senior Vice President of Operations & Integrated Supply Chain














CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price target for 2024?

4 analysts have issued 12-month price objectives for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2023?

Cytek Biosciences' stock was trading at $10.21 at the start of the year. Since then, CTKB stock has decreased by 27.3% and is now trading at $7.42.
View the best growth stocks for 2023 here
.

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,380,000 shares, an increase of 5.8% from the October 31st total of 7,920,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 7.8 days. Currently, 7.2% of the shares of the company are short sold.
View Cytek Biosciences' Short Interest
.

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CTKB earnings forecast
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The business had revenue of $48 million for the quarter, compared to analyst estimates of $55.09 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.73% and a negative net margin of 7.61%.

What ETF holds Cytek Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (4.99%), New York State Common Retirement Fund (1.72%), Wellington Management Group LLP (1.07%), Northern Trust Corp (0.84%), Charles Schwab Investment Management Inc. (0.61%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -